Theodore Karrison to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Theodore Karrison has written about Clinical Trials, Phase III as Topic.
Connection Strength
1.125
-
Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. J Clin Oncol. 2015 Jan 01; 33(1):36-41.
Score: 0.466
-
Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):6-9.
Score: 0.411
-
Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51.
Score: 0.103
-
Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15.
Score: 0.096
-
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. Clin Genitourin Cancer. 2022 12; 20(6):510-514.
Score: 0.049